Hors catégorie climbs represent a pinnacle of achievement in cycling, a challenge that can be met only with the right combination of talent, preparation and perseverance. We aspire to demonstrate those same qualities in our pursuit of new solutions for patients.
Success in hors catégorie climbs depends on exceptional power-to-weight ratio. Those riders who, like our engineered tRNAs, combine impressive power with a small, efficient form, dominate in hors catégorie climbs.
Starting with foundational research on tRNA engineering from the Ahern laboratory, we have built a robust and expanding discovery and drug development platform. We are especially distinguished by leadership in three key areas.
There are more than 450 tRNAs encoded in the human genome. To navigate this complex biology, our team combines extensive expertise in tRNA and protein translation with pharmacology, disease biology, and translational science—disciplines critical for successful bench-to-bedside transition.
We are developing cell-specific delivery vehicles with low immunogenicity and high durability. We have demonstrated liver-specific delivery using lipid nanoparticles, and are exploring multiple conjugation solutions for extra-hepatic diseases.
Rigorous data collection and analysis is vital to translating our understanding of tRNA biology and disease into breakthrough therapies for patients. Each choice we make — from engineering tRNAs, to delivery modality and dosing, to safety and pharmacokinetics — is informed by computational analysis and verified by experimental biology.
HC Bioscience has deep expertise in tRNA, basic and translational biology, delivery systems, drug development, and computational analysis. We are open to and interested in strategic collaborations to further develop tRNA-based therapeutics for a broad spectrum of genetically defined diseases.
Contact: partners@hcbioscience.com
